Join to View Full Profile
2000 Stockton Blvd Suite 202Sacramento, CA 95817
Phone+1 916-734-3461
Fax+1 916-734-3591
Dr. Giermasz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2008 - 2011
UPMC Medical EducationResidency, Internal Medicine, 2005 - 2008
Medical University of WarsawClass of 1998
Certifications & Licensure
CA State Medical License 2008 - 2026
PA State Medical License 2005 - 2008
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Publications & Presentations
PubMed
- Fidanacogene Elaparvovec for Hemophilia B - A Multiyear Follow-up Study.John E J Rasko, Benjamin J Samelson-Jones, Lindsey A George, Adam Giermasz, Jonathan M Ducore
The New England Journal of Medicine. 2025-04-17 - Completion of Phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years.Annette von Drygalski M.D, Esteban Gomez, Adam Giermasz, Giancarlo Castaman, Nigel S Key
Blood Advances. 2025-04-06 - Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors.Amy Dunn, Yesim Dargaud, Yasmina Abajas, Manuel Carcao, Giancarlo Castaman
Haemophilia. 2025-01-01
Abstracts/Posters
- Updated Follow-up of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy in Adult Patien...Adam Giermasz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Efficacy and Safety in 15 Hemophilia B Patients Treated with the AAV Gene Therapy Vector Fidanacogene Elaparvovec and Followed for at Least 1 YearAdam Giermasz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- One Year Data from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia BAdam Giermasz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
ASH 2020: Update for the Alta Study, a Phase 1/2 Gene Therapy Trial of Giroctocogene Fitelparvovec (SB-525) in Adults with Severe Hemophilia ADecember 18th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
